Michaela L. Tsai

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail et al. · Nature Medicine · 2022 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani et al. · Clinical Cancer Research · 2021 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan, Maya Ridinger, Tara L. Lin et al. · Clinical Cancer Research · 2020 · 89 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Periodontal Disease as a Risk Factor for Bisphosphonate‐Related Osteonecrosis of the Jaw

Vivek Thumbigere‐Math, Bryan S. Michalowicz, James S. Hodges et al. · Journal of Periodontology · 2013 · 87 citations

Dentistry, Periodontics, Periodontology +17